Gosset Curate Biosciences General Information
Curate Biosciences develops a proprietary microfluidic-based cell processing system that enables virtually lossless, gentle separation of leukocytes from apheresis or culture samples. This system addresses key bottlenecks in the manufacturing of next-generation cell and gene therapies—especially CAR-T—by providing cleaner starting material faster, reducing vein-to-vein time, improving yields of healthy cells, and potentially enhancing clinical outcomes. Their technology has been validated by over ten partners including leading academic centers such as City of Hope integrating it into investigational CAR-T workflows. The company’s products are commercially available to biopharma companies and CDMOs supporting advanced therapy development.
Contact Information
United States
Drug Pipeline
No pipeline data available
Key Partnerships
City of Hope (integration into CAR-T manufacturing), multiple undisclosed biotechnology companies and CDMOs (>10 validation partners)
Curate Biosciences Funding
No funding data available